RNAi Message Board - Msg: 20298801

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : RNAi

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Thomas who wrote (249)	7/10/2004 8:02:26 PM
From: tuck	Read Replies (1) of 671

Since you folow RNAI, the company . . . >>Atugen Strikes Contract Research Deal with Eisai Subsidiary By a GenomeWeb staff reporter NEW YORK, July 8 (GenomeWeb News) - Atugen said this week that it has signed a contract research agreement with Eisai London Research Laboratories, a subsidiary of Japanese drug maker Eisai. Under the deal, Atugen will use its gene-silencing technologies to validate and optimize undisclosed drug targets provided by Eisai. Additional terms, including the financials, were not disclosed. This is Atugen's second research agreement this year with a Japanese pharmaceutical company. The company also announced a multi-year agreement with Sankyo on May 17.<< Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next